Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hsu

Showing results (331-340 of 361) with videos related to

Pageof 37
Sort By:
Chemmedchem|November 23, 2012
3D-QSAR-assisted drug design: identification of a potent quinazoline-based Aurora kinase inhibitorYi-Yu Ke, Hui-Yi Shiao, Yung Chang Hsu, et al.
Anticancer Research|January 4, 2012
A high-throughput cell-based screening for L858R/T790M mutant epidermal growth factor receptor inhibitorsWen-Hsing Lin, Jen-Shin Song, Tzu-Wen Lien, et al.
Plos One|January 14, 2014
Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancerWen-Hsing Lin, Teng-Kuang Yeh, Weir-Torn Jiaang, et al.
British Journal of Cancer|December 22, 2011
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AMLW-H Lin, W-T Jiaang, C-W Chen, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2012
3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)John T-A Hsu, Teng-Kuang Yeh, Shih-Chieh Yen, et al.
Chemmedchem|December 30, 2009
Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitorMohane Selvaraj Coumar, Ming-Tsung Tsai, Chang-Ying Chu, et al.
Chemmedchem|July 24, 2012
Anti-influenza drug discovery: identification of an orally bioavailable quinoline derivative through activity- and property-guided lead optimizationJiann-Yih Yeh, Mohane Selvaraj Coumar, Hui-Yi Shiao, et al.
Journal of Medicinal Chemistry|January 23, 2010
Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivativesJiann-Yih Yeh, Mohane Selvaraj Coumar, Jim-Tong Horng, et al.
Nature Communications|May 23, 2026
PD-1 regulates latent effector differentiation of thymic cytotoxic CD8<sup>+</sup> T cellsZhiming Mao, Jacob B Hirdler, Joanina K Gicobi, et al.
Science Advances|November 15, 2023
Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8<sup>+</sup> T cells via ME1 up-regulationJoanina K Gicobi, Zhiming Mao, Grace DeFranco, et al.
Pageof 37

Showing results (331-340 of 361) with videos related to

Sort By:
Pageof 37
Chemmedchem|November 23, 2012
3D-QSAR-assisted drug design: identification of a potent quinazoline-based Aurora kinase inhibitorYi-Yu Ke, Hui-Yi Shiao, Yung Chang Hsu, et al.
Anticancer Research|January 4, 2012
A high-throughput cell-based screening for L858R/T790M mutant epidermal growth factor receptor inhibitorsWen-Hsing Lin, Jen-Shin Song, Tzu-Wen Lien, et al.
Plos One|January 14, 2014
Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancerWen-Hsing Lin, Teng-Kuang Yeh, Weir-Torn Jiaang, et al.
British Journal of Cancer|December 22, 2011
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AMLW-H Lin, W-T Jiaang, C-W Chen, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2012
3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)John T-A Hsu, Teng-Kuang Yeh, Shih-Chieh Yen, et al.
Chemmedchem|December 30, 2009
Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitorMohane Selvaraj Coumar, Ming-Tsung Tsai, Chang-Ying Chu, et al.
Chemmedchem|July 24, 2012
Anti-influenza drug discovery: identification of an orally bioavailable quinoline derivative through activity- and property-guided lead optimizationJiann-Yih Yeh, Mohane Selvaraj Coumar, Hui-Yi Shiao, et al.
Journal of Medicinal Chemistry|January 23, 2010
Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivativesJiann-Yih Yeh, Mohane Selvaraj Coumar, Jim-Tong Horng, et al.
Nature Communications|May 23, 2026
PD-1 regulates latent effector differentiation of thymic cytotoxic CD8<sup>+</sup> T cellsZhiming Mao, Jacob B Hirdler, Joanina K Gicobi, et al.
Science Advances|November 15, 2023
Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8<sup>+</sup> T cells via ME1 up-regulationJoanina K Gicobi, Zhiming Mao, Grace DeFranco, et al.
Pageof 37